Kenneth J Woodside1, Sarah Bell2, Purna Mukhopadhyay3, Kaitlyn J Repeck3, Ian T Robinson2, Ashley R Eckard2, Sudipta Dasmunshi2, Brett W Plattner4, Jeffrey Pearson3, Douglas E Schaubel5, Ronald L Pisoni3, Rajiv Saran6. 1. Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI; Department of Surgery, University of Michigan, Ann Arbor, MI. 2. Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI. 3. Arbor Research Collaborative for Health, University of Michigan, Ann Arbor, MI. 4. Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. 5. Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI; Department of Biostatistics, University of Michigan, Ann Arbor, MI. 6. Kidney Epidemiology and Cost Center, University of Michigan, Ann Arbor, MI; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Department of Epidemiology, University of Michigan, Ann Arbor, MI. Electronic address: rsaran@umich.edu.
Abstract
BACKGROUND: Arteriovenous fistulas (AVFs) are the preferred form of hemodialysis vascular access, but maturation failures occur frequently, often resulting in prolonged catheter use. We sought to characterize AVF maturation in a national sample of prevalent hemodialysis patients in the United States. STUDY DESIGN: Nonconcurrent observational cohort study. SETTING & PARTICIPANTS: Prevalent hemodialysis patients having had at least 1 new AVF placed during 2013, as identified using Medicare claims data in the US Renal Data System. PREDICTORS: Demographics, geographic location, dialysis vintage, comorbid conditions. OUTCOMES: Successful maturation following placement defined by subsequent use identified using monthly CROWNWeb data. MEASUREMENTS: AVF maturation rates were compared across strata of predictors. Patients were followed up until the earliest evidence of death, AVF maturation, or the end of 2014. RESULTS: In the study period, 45,087 new AVFs were placed in 39,820 prevalent hemodialysis patients. No evidence of use was identified for 36.2% of AVFs. Only 54.7% of AVFs were used within 4 months of placement, with maturation rates varying considerably across end-stage renal disease (ESRD) networks. Older age was associated with lower AVF maturation rates. Female sex, black race, some comorbid conditions (cardiovascular disease, peripheral artery disease, diabetes, needing assistance, or institutionalized status), dialysis vintage longer than 1 year, and catheter or arteriovenous graft use at ESRD incidence were also associated with lower rates of successful AVF maturation. In contrast, hypertension and prior AVF placement at ESRD incidence were associated with higher rates of successful AVF maturation. LIMITATIONS: This study relies on administrative data, with monthly recording of access use. CONCLUSIONS: We identified numerous associations between AVF maturation and patient-level factors in a recent national sample of US hemodialysis patients. After accounting for these patient factors, we observed substantial differences in AVF maturation across some ESRD networks, indicating a need for additional study of the provider, practice, and regional factors that explain AVF maturation.
BACKGROUND:Arteriovenous fistulas (AVFs) are the preferred form of hemodialysis vascular access, but maturation failures occur frequently, often resulting in prolonged catheter use. We sought to characterize AVF maturation in a national sample of prevalent hemodialysis patients in the United States. STUDY DESIGN: Nonconcurrent observational cohort study. SETTING & PARTICIPANTS: Prevalent hemodialysis patients having had at least 1 new AVF placed during 2013, as identified using Medicare claims data in the US Renal Data System. PREDICTORS: Demographics, geographic location, dialysis vintage, comorbid conditions. OUTCOMES: Successful maturation following placement defined by subsequent use identified using monthly CROWNWeb data. MEASUREMENTS: AVF maturation rates were compared across strata of predictors. Patients were followed up until the earliest evidence of death, AVF maturation, or the end of 2014. RESULTS: In the study period, 45,087 new AVFs were placed in 39,820 prevalent hemodialysis patients. No evidence of use was identified for 36.2% of AVFs. Only 54.7% of AVFs were used within 4 months of placement, with maturation rates varying considerably across end-stage renal disease (ESRD) networks. Older age was associated with lower AVF maturation rates. Female sex, black race, some comorbid conditions (cardiovascular disease, peripheral artery disease, diabetes, needing assistance, or institutionalized status), dialysis vintage longer than 1 year, and catheter or arteriovenous graft use at ESRD incidence were also associated with lower rates of successful AVF maturation. In contrast, hypertension and prior AVF placement at ESRD incidence were associated with higher rates of successful AVF maturation. LIMITATIONS: This study relies on administrative data, with monthly recording of access use. CONCLUSIONS: We identified numerous associations between AVF maturation and patient-level factors in a recent national sample of US hemodialysis patients. After accounting for these patient factors, we observed substantial differences in AVF maturation across some ESRD networks, indicating a need for additional study of the provider, practice, and regional factors that explain AVF maturation.
Authors: Jordan R Casey; Camilla S Hanson; Wolfgang C Winkelmayer; Jonathan C Craig; Suetonia Palmer; Giovanni F M Strippoli; Allison Tong Journal: Am J Kidney Dis Date: 2014-08-10 Impact factor: 8.860
Authors: Michael Allon; Lesley Dinwiddie; Eduardo Lacson; Derrick L Latos; Charmaine E Lok; Theodore Steinman; Daniel E Weiner Journal: J Am Soc Nephrol Date: 2011-02-18 Impact factor: 10.121
Authors: Rachel B Fissell; Douglas S Fuller; Hal Morgenstern; Brenda W Gillespie; David C Mendelssohn; Hugh C Rayner; Bruce M Robinson; Dori Schatell; Hideki Kawanishi; Ronald L Pisoni Journal: J Vasc Access Date: 2013-04-10 Impact factor: 2.283
Authors: Laura M Dember; Gerald J Beck; Michael Allon; James A Delmez; Bradley S Dixon; Arthur Greenberg; Jonathan Himmelfarb; Miguel A Vazquez; Jennifer J Gassman; Tom Greene; Milena K Radeva; Gregory L Braden; T Alp Ikizler; Michael V Rocco; Ingemar J Davidson; James S Kaufman; Catherine M Meyers; John W Kusek; Harold I Feldman Journal: JAMA Date: 2008-05-14 Impact factor: 56.272
Authors: Ronald L Pisoni; Charlotte J Arrington; Justin M Albert; Jean Ethier; Naoki Kimata; Mahesh Krishnan; Hugh C Rayner; Akira Saito; Jeffrey J Sands; Rajiv Saran; Brenda Gillespie; Robert A Wolfe; Friedrich K Port Journal: Am J Kidney Dis Date: 2009-01-15 Impact factor: 8.860
Authors: Angharad Marks; Nicholas Fluck; Gordon J Prescott; Lynn Robertson; William G Simpson; William Cairns Smith; Corri Black Journal: Nephrol Dial Transplant Date: 2015-05-05 Impact factor: 5.992
Authors: Shipra Arya; Taylor A Melanson; Elizabeth L George; Kara A Rothenberg; Manjula Kurella Tamura; Rachel E Patzer; Jason M Hockenberry Journal: J Am Soc Nephrol Date: 2020-01-15 Impact factor: 10.121